Zio­pharm craters on re­port of pa­tient death in gene ther­a­py study

Shares of Zio­pharm $ZIOP plunged this morn­ing af­ter Adam Feuer­stein at TheStreet broke the sto­ry that one pa­tient in its gene ther­a­py study dubbed Ad-RTS-hIL-12 died due to an in­tracra­nial he­m­or­rhage 15 days af­ter start­ing treat­ment. The note on the death — one of sev­er­al — was in­clud­ed in a slide pre­sen­ta­tion filed with the SEC. No­tably, Feuer­stein had the re­port even be­fore FDA reg­u­la­tors were no­ti­fied.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER